Rapafusyn Pharmaceuticals Funding Round

6/24/2024

Venture Equity

$28,000,000

Series A

The company intends to use the funds to accelerate the progress of its pipeline of macrocyclic peptide-based non-degrading molecular glues and further enhance its internal capabilities.

Private & Independent

Biopharmaceutical

855 N. Wolfe Street
Baltimore, MD 21205
USA

At Rapafusyn, we are developing non-degrading molecular glues to tackle difficult drug targets to improve patient outcomes. Rapafusyn has designed and generated large DNA encoded libraries (DELs) and arrayed libraries of non-degrading molecular glues (RapaGlues�) that are designed on a FKBP-binding macrocyclic peptide platform. These libraries have been successful in generating novel chemical starting points for hard-to-drug targets, often with cell permeability right from screening. Moreover, as our molecules are molecular glues, the target-binding peptidic portion is more tunable than traditional macrocyclic peptides.